Group One Trading’s GT Biopharma GTBP Stock Holding History

Group One Trading’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-7	Closed	-$1K	–	8070
2022 Q1	$1K	Sell	7 -30	-81%	-$2.65K	﹤0.01%	7832
2021 Q4	$3K	Buy	+37	New	+$5.54K	﹤0.01%	7783

Other funds holding GTBP

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BFS

Baskin Financial Services Toronto, Ontario, Canada $1.27B AUM 9.68% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Group One Trading's GTBP Position: Q4 2022 in Review

Group One Trading sold out of GT Biopharma (GTBP) in Q4 2022, closing a stake of 4 shares.

Group One Trading first reported a position in GTBP in Q1 2022 and held it in 3 quarters. The position peaked at $52K in Q2 2022. 36 funds tracked by Wall St. Rank hold GTBP as of Q4 2022.

Group One Trading reported no remaining GT Biopharma position as of Q4 2022 after selling out during the quarter.
Group One Trading sold 4 GT Biopharma shares in Q4 2022.
Group One Trading first reported a position in GT Biopharma in Q1 2022 and held it in 3 quarters.
Group One Trading's GT Biopharma position peaked at $52K in Q2 2022.
36 funds tracked by Wall St. Rank held GT Biopharma as of Q4 2022.

Based on Group One Trading's 13F filing for Q4 2022, filed 9 Feb 2023.